Verustat Expands Service With DCT Support
New all-in-one solution to increase compliance and accuracy.
Verustat has expanded its services to provide multiple levels of support for decentralized clinical trials (DCT). Verustat's customizable SELECT DCT offering is a streamlined solution that can offer increased compliance, stability, and accuracy.
The DCT program was designed to enhance the patient experience and improve compliance at the patient’s home. Each DCT can be customized to the patient’s requirements. Service offerings include Verustat’s RPM platform, telemedicine visits, medical peripheral hardware sourcing, multiple communication methods, global customs management, Tier 2 technical support, and equipment leasing.
Read more about Verustat
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
